Lyra Therapeutics Inc (LYRA) - Total Liabilities
Based on the latest financial reports, Lyra Therapeutics Inc (LYRA) has total liabilities worth $46.83 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Lyra Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Lyra Therapeutics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Lyra Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see LYRA total assets.
Lyra Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Lyra Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dewhurst
LSE:DWHT
|
UK | GBX10.81 Million |
|
Ortivus AB ser. A
ST:ORTI-A
|
Sweden | Skr56.06 Million |
|
Predator Oil & Gas Holdings Plc
LSE:PRD
|
UK | GBX10.58 Million |
|
Hercules Site Services PLC
LSE:HERC
|
UK | GBX28.70 Million |
|
Amigo Holdings PLC
LSE:AMGO
|
UK | GBX39.20 Million |
|
China Liberal Education Holdings
NASDAQ:CLEU
|
USA | $5.30 Million |
|
PBT Group Ltd
JSE:PBG
|
South Africa | ZAC103.88 Million |
|
Glob Bioenergi
PA:ALGBE
|
France | €7.96 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Lyra Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Lyra Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lyra Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lyra Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Lyra Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $46.83 Million | -14.48% |
| 2024-12-31 | $54.75 Million | +2.96% |
| 2023-12-31 | $53.18 Million | +82.04% |
| 2022-12-31 | $29.21 Million | +42.15% |
| 2021-12-31 | $20.55 Million | +224.25% |
| 2020-12-31 | $6.34 Million | -16.99% |
| 2019-12-31 | $7.63 Million | -94.23% |
| 2018-12-31 | $132.43 Million | -- |
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-infla… Read more